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Changes in plasma 1,25- and 24,25-dihydroxyvitamin D after renal
transplantation in children. The purpose of this investigation is to
analyze changes in plasma l,25-(OH)2D and 24,25-(OH)2D after suc-
cessful renal transplantation in 20 children and young adults. Studies
were performed on 8 subjects between the 1st and 10th month and on 12
others between the 20th and 30th to 36th month. Samples were assayed
for plasma and urinary calcium, inorganic phosphate, creatinine, plas-
ma bicarbonate, immunoreactive parathyroid hormone, 25-(OH)D, 24,
25-(OH)2D, and 1,25-(OH)2D concentrations. Results showed the fol-
lowing: (1) All subjects had normal or high plasma levels of dihydroxy-
vitamin D metabolites. (2) In subjects with normal GFR's there was a
significant inverse correlation between plasma 1,25 -(OH),D and phos-
phate concentrations and between plasma 1 ,25-(OH)2D concentrations
and tubular reabsorption of phosphorus. (3) These correlations were not
found in subjects with subnormal creatinine clearances (50 to 100 mu
min/l.73 m2) even though plasma 1,25-(OH)2D concentrations in these
subjects were similar to those with normal creatinine clearances. (4) In
subjects with subnormal creatinine clearances, an increase in plasma
1 ,25-(OH)2D concentrations to very high levels was observed during the
first months following renal transplantation.
Evolution des concentrations plasmatiques de 1,25- et 24,25-dihydroxy-
vitamine D apres transplantation rénale chez l'enfant. Le but de cc
travail a été d'analyser l'évolution des concentrations plasmatiques de
1,25-(OH)2D et de 24,25-(OH)2D après une transplantation rénale
réussie chez 20 enfants et adultes jeunes. Huit sujets ont été étudiés
entre Ic Icr et Ic l0è mois et 12 autres entre le 20è et le 30 a 36è mois.
Les determinations suivantes ont été obtenues: calcium plasmatique et
urinaire, phosphate inorganique, créatinine, bicarbonate plasmatique,
hormone parathyroidienne immuno-rëactive, concentration plasma-
tique de 25-(OH)D, 24,25-(OH)2D, et l,25-(OH)2D. Les résultats ont
montré que: (1) Tous les sujets avaient des concentrations plasmatiques
normales ou élevées de métabolites dihydroxyles de Ia vitamine D. (2)
Chez les sujets ayant des GFR's normaux il existait une correlation
inverse entre les concentrations plasmatiques de 1 ,25-(OH)2D et de
phosphate et entre Ia concentration plasmatique de 1 ,25-(OH)2D et Ia
reabsorption tubulaire du phosphate. (3) Ces correlations n'ont pas été
observCes chez les sujets dont les clairances de La créatinine étaient
inférieures a Ia normale (50 a 100 mllmin/1,73 m2) bien que les
concentrations plasmatiques de l,25-(OH)2D de ces sujets étaient
semblables celles des sujets dont les clairances de Ia créatinine étaient
normales. (4) Chez les sujets dont les clairances de Ia créatinine étaient
inférieures a Ia normale une augmentation très importante de Ia
concentration plasmatique de 1 ,25-(OI-fl2D a eté observée au cours des
premiers mois consécutifs a Ia transplantation.
[OH]2D) [I]. In kidney necrograft recipients, circulating levels
of I,25-(OH)2D have been detected [2—61 and, although not yet
reported, it seems reasonable to expect a 24,25-(OH)2D synthe-
sis in the transplanted kidney. No information is yet available
on the regulation of the plasma vitamin D metabolites after
kidney transplantation.
The purpose of the present work is to analyze in 20 children
and young adults: (1) the ability of the adult transplanted kidney
to produce vitamin D metabolites, and (2) the evolution of
circulating vitamin D metabolites in relation to the evolution of
factors known to regulate plasma 1,25-(OH)2D and 24,25-
(OH)2D. Two sequential investigations have been carried out,
one at an early stage (8 patients between the 1st and 6th to 10th
month), and the other during a more stable period (12 other
patients between the 20th and 30th to 36th month), following
renal transplantation.
Methods
Twenty patients, aged 4 to 20 years at the time of transplanta-
tion, have been followed according to two different protocols.
Short-term posttransplant protocol. The first protocol con-
cerns all subjects having received a kidney graft between
October 1978 and March 1979 in the Department of Pediatric
Nephrology (Prof. M. Broyer) and for whom a followup during
at least 6 months has been possible (8 patients aged 4 to 17
years).
Until the date of transplantation, all patients had been on
chronic hemodialysis and had received vitamin D supplementa-
tion (Table 1). Child 8 was anephric at the time of transplanta-
tion. Child 3 had undergone, 11 months prior to kidney trans-
plantation, a total parathyroidectomy with autotransplantation
of 70 mg of parathyroid tissue in the supinator longus muscle.
None of the children had radiologic lesions of osteomalacia.
Only child 3, had radiologic signs of hyperparathyroidism.
For transplantation, sources of the kidneys used were from
adult cadaveric donors. HL-A identities between grafts and
In the recent years, the kidney has been proven to be a major
organ for the synthesis of two vitamin D active metabolites,
1,25- and 24,25-dihydroxyvitamin D (1,25-[OH]2D and 24,25-
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Table 1. Clinical data for patients of protocol I at the time of kidney transplantation
On chronic
Age Heighta hemodialysis Type of vitamin D iPTH 25-(OH)D
Patient no. Sex years Sn Primary disease months therapyb ng/ml nmoles/liier
M 9 3 Cystinosis 16 25-(OH)D3 0.38 60
2 M 13 3 Anaphylactoid purpura 31 25-(OH)D3 1.80 38
3 M 4 4 Urinary tract malformation 18 l,25-(OH)2D3 0.44 48
4 F 15 5 Hypoplasia + dysplasia 37 la-(OH)D3 0.50 19
5 M 16 6 Nephronophtisis 17 la-(OH)D3 0.37 14
6 M 17 5 Nephronophtisis 64 25-(OH)D3 0.82 139
7 F 12 2.5 Segmental and focal hyalinosis 18 la-(OH)D3 0.31 7
8 F 13 5 Cystinosis 41 lct-(OH)D3 0.54 17
Height is expressed as standard deviations below the mean for chronological age.
The vitamin D metabolites or analogs had been given for more than 1 month before and up to the day of kidney tranplantation.
Table 2. Posttransplant therapy in patients of protocol la
Time of therapy, months
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Prednisone:
Ito 1.6 mg/kglday 0—I 0—I 0.-I 0—1 0—5 0—1 0—5 0—2
0.3 to 0.5 mg/kg/day 1—10 1—10 1—10 1—10 5—10 1—10 5—10 2—10
Therapy for acute rejection — — — — 2,5,9 — 4,5 1
P04 supplementation — — — — 1—6 — 2—6 2—4
Antihypertensive drugs 0—2 — — — 3—6 — 0—10 0—2
Chlorothiazide — 1—12 — — — — — —
Furosemide — — — — 3—6 1—3 1—6 1—3
Cimetidine — — — 0.5—5 — — — —
25-(OH)D3 1—10 1—10 1—10 1—10 1—10 1—10 1—8 1—10
a The therapeutical agents shown on this table are the ones which have not been prescribed similarly to all subjects. Numbers represent the limits
of the administration periods (in months after kidney transplantation) or the months when therapy was given (acute rejection episodes).
recipients were 2 to 4. The warm and cold ischemia times of the
graft were 1 to 5 mm and 2 to 26 hours, respectively.
Biochemical and radioimmunologic data were collected dur-
ing the posttransplant period from the beginning of the 2nd
month to the 6th—lOth month. Data gathered during the first
month have not been considered to minimize the possible
influence of pretransplant vitamin D intake on plasma vitamin D
metabolites. (As noted in Table 1, subjects on la-(OH)D3
therapy had low 25-(OH)D levels at the time of transplantation.)
Posttransplant therapy combined (I) immunosuppressive
treatment with azathioprine (2.4 to 3.3 mg/kg/day) and predni-
sone (ito 1.6 mg/kg/day during the first month, then decreasing
doses to 0.3 to 0.5 mg/kg/day); (2) calcium (0.4 to 0.8 glday of
elemental calcium) and 25 p.g/day 25-(OH)D3 (that is, 0.6 to 2,2
p.glkg/day); (3) oral phosphate supplementation (0.5 to 1.2 g/
day) for three children; (4) antihypertensive drugs (5 patients);
(5) diuretics (5 patients). Individual treatments and acute rejec-
tion episodes are presented in Table 2 and Figs. I and 3.
Long-term posttransplant protocol. The second protocol
concerns 12 children and young adults selected among the 1976
allograft recipients on the basis of a satisfactory renal function
from the 6th to the 3Oth—36th month after renal transplantation.
The arbitrary required minimum level for creatinine clearance
was defined as 50 ml/min/l.73 m2 or over. The subject ages
ranged from 7 to 20 years at the time of transplantation (January
to December 1976). Before transplantation, all patients had
been on chronic hemodialysis for 7 to 36 months. As in the first
protocol, sources of the kidneys used were from children or
adult cadaveric donors.
The investigation period started at the 20th month and lasted
up to the 3Oth—36th month following renal transplantation,
because it had not been possible to assay 1 ,25-(OH)2D in the
plasma of these patients before the 20th month. During the
study period, all patients received immunosuppressive treat-
ment (azathioprine, 1.7 to 3 mg/kg/day; prednisone, 0.2 to 0.4
mg/kg/day or 0.8 mg/kg every other day; and 25-(OH)D3, 15 to
35 pg/day. Seven children received antihypertensive drugs
(patients 9, 10, 11, 13, 15, 19, 20). Child 19 received an oral
phosphorus supplementation of 1.5 glday. The patients received
aluminium phosphate antacids but no hydroxide antacids. An
acute rejection episode occurred once in patient 14 and once in
patient 17.
Parameters studied and techniques. Plasma calcium, inor-
ganic phosphate, creatinine, alkaline phosphatases, total pro-
tein, sodium, potassium, chloride, and bicarbonate concentra-
tions were measured regularly in blood samples collected in the
morning after an overnight fast, one to three times monthly
during the 1st to 10th month and during the 20th to 36th month.
Simultaneously, creatinine clearances and calcium and phos-
phate urinary excretions were measured on 24-hour urine
specimens. Urine samples were examined at regular intervals
for the presence of reducing sugars and for qualitative and
quantitative determination of aminoaciduria. 25-Hydroxyvita-
mm D (25-[OH]D), 24,25-[OH]2D, 1 ,2540H]2D) and iPTH were
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Fig. 1. Evolution of biochemical parameters during the first /0 months
of renal transplantation in four patients with normal GFR. Biochemical
parameters are creatinine clearances, plasma concentrations of calcium
(corrected for protide concentrations), inorganic phosphate, immunore-
active parathyroid hormone, I ,25-(OH)2D. Normal ranges for the age
(mean 1 SD) are indicated for each parameter. The higher limit for
normal plasma iPTH concentration in adults is indicated by a dotted
line. Plasma l,25-(OH)2D concentrations have been measured after
Sephadex LH2O, then high-pressure liquid chromatography using either
a reverse-phase system (closed circles) or a straight-phase system
(closed triangles).
assayed on the same plasma sample once a month when
possible in the first protocol and one to four times for each
patient of the long-term protocol.
The following techniques were used: for plasma and urinary
calcium, an atomic spectrophotometry (Perkin Elmer); for
plasma and urinary phosphorus and creatinine, plasma bicar-
bonate and total protein, an autoanalyzer (Technicon, Domont,
France); for plasma alkaline phosphatases, a method adapted to
an autoanalyzer; for plasma 25-(OH)D [7], a competitive pro-
tein assay. Plasma 24,25-(OH)2D and 1,25-(OH)2D were mea-
sured using the competitive protein assays of Nguyen et al [8]
and of Shepard eta! [91, respectively, after (a) extraction of Ito
2 ml of plasma with a mixture of methanol-chloroform, (b)
chromatography of the chloroform phase on a Sephadex LH 20
column with 55% chloroform-n hexan as solvent, (c) chroma-
tography of the 24,25-(OH)2D3 peak fractions (eluted from
Sephadex LH 20 column) on a high-pressure liquid system
(Waters Associate) using a 1iC18 column, an elution gradient
over 40 mm of 50 to 100% methanol-water as solvent, and a flow
rate of 2 mI/mn [8], (d) chromatography of the l,25-(OH)7D3
peak fractions (eluted from Sephadex LH 20 column) on a high-
pressure liquid system using either a micro-Bondapak C15
column and an elution gradient of 50 to 100% methanol-water as
solvent (76 samples), or a micro-porasil column with a 90%
hexane-isopropanol solvent (13 samples) and a flow rate of 2 ml!
mm [9]. Plasma 24,25-(OH)2D values are 1.7 to 7.2 nmoles/liter
(mean I SD) in 26 normal children aged 2 to 17 years [8].
Plasma 1,25-(OH)2D concentrations in 18 normal adults are 24
to 155 pmoles/liter (mean 1 SD). Normal values for 1,25-
(OH)2D are not different after high-liquid pressure chromatog-
raphy of the sample with a reverse phase or with a straight
phase. Plasma iPTH assay utilized a carboxy terminal antise-
rum; all values are expressed as equivalents of purified bovine
PTH. The lower limit of detection is 0.05 ng/ml. Values in
normal adults are lower than 0.5 ng/ml. Values in normal
children are 0.3 ng/ml, with a range from < 0.05 to 0.5 ng/ml.
Results
(1) Changes in plasma vitamin D metabolites in the 10 first
months after renal transplantation (short-term protocol). A first
analysis of the data showed that variations of plasma 1,25-
(OH)2D concentrations in the four patients with a totally
restored glomerular function (Figs. 1 and 2) could not be
superimposed on those found in the four patients with a less
satisfactory glomerular function (Figs. 3 and 4). To clarify the
presentation, we will report data from this protocol in two
sections according to the GFR of the patients.
(a) Plasma vitamin D metabolites in patients with GFR's
equal to or over 100 ml/minll.73 m2. Four of the eight patients
belong to this group (Figs. I and 2, Table 3). The GFR's
remained high during the investigation in three subjects, and
decreased after the 7th month of transplantation in the fourth
patient (data obtained thereafter for this child no. 2 have
therefore not been included in the present analysis).
Three of the patients had normal plasma calcium and phos-
phate concentrations, normal urinary calcium excretions (0.02
to 0.1 mmoles/kg of body wt per 24 hr), and tubular reabsorp-
tion of phosphate (77 to 92%). They did not have proteinuria,
glycosuria, or elevated aminoaciduria. Patient 4 exhibited peri-
ods of hypophosphatemia with low tubular reabsorption of
phosphate (40 to 70%), high urinary calcium excretions (0.15 to
0.25 mmoles/kg/day), and glycosuria. Plasma bicarbonate, sodi-
um, potassium, and chloride concentrations were found to be
within the normal range (except for child 2 who received
chlorothiazide).
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Fig. 2. Evolution ofplasma I.25-(OH),D, 24, 25-(OH)-J) and 25-(OH)I3
concentrations in the four patients with normal GFR shown in Fig. I.
See details under Fig. I.
406 Garabedian et al
oW-.
E
a,
8
8
088
'8
Patient 5 Patient 6 Patient 7 Patient 8
2 4 6 8 10 2 4 6 8 10 2 4 6 8 10 2 4 6 8 10
Time, months
Fig. 3. Evolution of biochemical parameter during the first 10 months of
renal transplantation in four patients with subnorsnal GFR. See details
under Fig. 1.
Plasma immunoreactive parathyroid hormone (iPTH) de-
creased in all four patients. It reached normal levels after 3 to 7
months in three patients and remained above normal range in
patient 2. Plasma 25-(OH)D concentrations remained in the
normal range during the first 3 to 6 months. It increased above
the normal range during the months of June and July 1978
although 25-(OH)D3 intake had not been modified (this corre-
sponded to the 7th, 7th, 6th, and 3rd month, respectively, of
study in children ito 4). Plasma dihydroxyvitamin D metabolite
concentrations were high when compared with normal non-
transplanted children and adolescents [8, 10, 111. Their evolu-
tions did not parallel that of their precursor 25-(OH)D. No
correlation was found between simultaneously measured 25-
(OH)D and 24,25-(OH)2D or 1,25-(OH)2D, 24,25-(OH)2D and
1 ,25-(OH)2D. No change in treatment could account for the
observed changes in 1 ,25-(OH)2D and 24,25-(OH)2D plasma
concentrations. Trials to correlate l,25-(OH)2D or 24,25-
(OH)2D with iPTH plasma concentrations failed. Trials to
correlate one of the dihydroxymetabolites with other biochemi-
cal parameters brought out two significant negative correla-
tions: between plasma I ,25-(OH)2D and phosphate concentra-
tions assayed on the same sample (Fig. 5) and between plasma
1 ,25-(OH)2D concentrations and tubular reabsorption of phos-
phate measured on 24-hour urine collections (y = — 16x + 1691,
r =
—0.632, P < 0.02).
During the followup, growth rate was 0.5 cm/rn in child 1, 0.8
cm/rn in child 2. No growth was observed for children 3 and 4.
(b) Plasma vitamin D metabolites in patients with GFR's
below 100 ml/minll.73 m2. Four subjects belong to this group
(Figs. 3 and 4, Table 3). All subjects had GFR's between 50 and
100 ml/min/l.73 m2 except patients 6 and 8 during 2- and 4-
month periods. Plasma calcium, when corrected for plasma
Patient 5 Patient 6 Patient 7 Patient 8
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Fig. 4. Evolution of plasma i,25-(OH)2D, 24,25-(OH)2D, and 25-(OH)D
concentrations in the four patients with subnormal GFR shown in Fig.
3. See details under Fig. 1.
proteins [12], was found to be in the normal range. In three of
the four children, plasma phosphate concentrations were below
or at the lower limit of the normal range for their age. Plasma
bicarbonate concentrations were in the normal range in the four
children except during furosernide treatment (plasma bicarbon-
ates rose then up to 17 to 20 mmoles/liter). During this treat-
ment, plasma potassium fell to 2.5 to 3.0 mmoles/liter, plasma
chloride to 85 to 90 rnmoles/liter, and plasma sodium remained
within the normal range. Urinary calcium excretion and tubular
reabsorption of phosphate have not been considered because of
furosemide and phosphate supplementations for long periods of
time. No proteinuria was observed. Glycosuria with elevated
aminoaciduria were detected in child 5 during the 10 months of
investigation.
Parathyroid hormone concentrations increased in all four
cases at the 3rd to 6th month after kidney transplantation (Fig.
3). A peak was also observed in I ,25-(OH)7D plasma concentra-
tions at the 3rd to 6th month. Maximum levels reached were
extremely high (1.2 to 2.9 nmoles!liter). The biological activity
of the first plasma sample obtained in patient 7 has been tested
in vitro using the increase in bone phosphatase activities as an
index [13]. After extraction and double-step chromatography
(on Sephadex LH 20 column, then on high-pressure liquid
system), the l,25-(OH)2D fraction of this plasma was found to
contain 1.20 nmoles/liter as measured by competitive protein
assay and 1.52 nmoles/liter as measured by the increase in
calvarium acid and alkaline phosphatase content. An important
rise preceding or simultaneous to the I ,25-(OH)2D increase was
also observed for 24,25-(OH)2D in the four patients, although it
was small for child 8 (Fig. 4). A parallelism was observed
between plasma I ,25-(OH)2D and 24,25-(OH)2D changes in
children 6 and 8 but not in children 5 and 7. In these latter
patients, concentrations of 24,25-(OH)2D remained high up to
the 10th month of investigation, whereas plasma 1,25-(OH)2D
had decreased. in the four children, 25-(OH)D circulating levels
increased after June 1979. As in group 1, the evolution of the
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Table 3. Biochemical data in subjects of protocol 1 from the 1st to the 8th month after successful renal transplantation.a
Patients I to 4 Patients 5 to 8
1st to 6th month 6th to 8th month 1st to 6th month 6th to 8th month
Plasma concentrations
Creatinine, p.moleslliter 56 II 52 9 103 26 100 28
Calciumb, mmoleslliter 2.49 0.07 2.47 0.07 2.47 0.02 2.51 0.02
Phosphate, mmoleslliter 1.20 0.19 1.30 0.11 1.03 0.18 1.04 0.15
Bicarbonate, mmOles/liter 12.8 1.9 13.0 0.6 14.5 1.2 12.5 0.9
25-(OH)D, nmoles/liter 61 25 97 28 37 19 100 28
24,25-(OH)2D, nmoleslliter 12 3 9 8 17 10 16 26
l,25-(OH)2D, pmoleslliter 372 50 349 161 2076 649 300 60
iPTH, nglml 0.68 0.60 0.34 0.31 0.66 0.16 0.28 0.14
Other parameters
Creatinine clearance,
mlIminII.73 m2 123 30 113 16 83 14 80 18
Urinary calcium excretion,
mmoleslkg body wt/day 0.06 0.04 0.05 0.04 0.03 0.002 0.07 0.02
Tubular reabsorption of
phosphorus, % 80 7 88 0.5 51 22 66 3
a All data are given as means SD of mean values obtained for each subject. The individual mean values have been calculated with all data from
serial measurements performed between the 1St and 6th, and 6th and 8th month after renal transplantation. Subjects Ito 4 (aged 9 to 15 years) and 5
to 8 (aged 12 to 17 years) are presented in two groups according to their GFR.
b Plasma calcium concentrations have been corrected for plasma proteins [12].
Significant differences between subjects I to 4 and 5 to 8 are noted: P < 0.05.
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Fig. 5. Correlation between 1,25-(OH)2D and phosphate concentrations
measured simultaneously on plasma samples during the first year from
children and young adults with successful kidney transplants. Left panel
Patients Ito 4 with creatinine clearances of 100 mlIminII.73m2 or over.
Data from all blood samples, in which both 1 ,25-(OH)2D and phosphate
concentrations could be measured, have been used. Right panel Pa-
tients 5 to 8 with creatinine clearances below 100 ml/min/I.73 m2. Only
the data obtained after the initial peak of I ,25-(OH)2D concentrations
have been used.
dihydroxymetabolite concentrations in plasma were indepen-
dent from that of 25-(OH)D.
No growth was observed in any of the four children during
the study period. No change in treatment, or in biochemical,
radioimmunologic, or radiologic parameters could be correlated
with 24,25-(OH)2D evolution in plasma. Neither could the initial
peak in 1 ,25-(OH)2D concentrations be correlated to any of the
measured parameters. Its appearance was, however, always
associated with low GFR's (60 to 85 ml/min/1.73 m2) and high
circulating iPTH levels. It did not occur systematically while
prednisone dosage was high nor during acute rejection therapy
(Fig. 3, Table 2). It did not coincide with antihypertensive drugs
or chiorotiazide administration. But high plasma concentrations
0.75 1.0 1 25 1.50
P1, mrnoles/Iiter
Fig. 6. Correlation between I ,25-(OH),D and phosphate concentrations
measured simultaneously on plasma samples from children and young
adults with successful kidney transplants between the 20th and 30th—
36th month of transplantation. Data from all blood samples, in which
both 1 ,25-(OH)2D and phosphate concentrations could be measured,
have been used. Left panel Patients 9 to 13 and patient 14 with
creatinine clearances of 100 ml/min/l.73 m2 or over. Right panel
Patients 15 to 20 and patients II and 14 (2nd period) with creatinine
clearances below 100 mI/mini] .73 m2.
of 1 ,25-(OH)2D have often been found during furosemide ad-
ministration (8 out of 10 samples).
After the initial peak, I ,25-(OH)2D plasma concentrations
returned to lower values in the four patients, between the 3rd
and 10th month after transplantation irrespective of GFR's (Fig.
3), iPTH levels, plasma 25-(OH)D concentrations, or treatment
(Table 2). At this stage, plasma 1,25-(OH)2D concentrations
could not be correlated with any of the biochemical parameters,
and the negative correlation found in group 1 between plasma
1 ,25-(OH)2D and phosphate concentrations has not been ob-
served in group 2 (Fig. 5). There was also no correlation
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Table 4. Biochemical data in subjects of protocol 2 from the 20th to the 30th to 36th month after successful renal transplantation.
Patients 9 to 13 Patients 15 to 20
Patient 14
1st period 2nd period
Plasma concentrations
Creatinine, p.moles/liter 72 II 108 12c 91 135
Calciumb, mmo!es/liter 2.50 0.1 2.50 0.05 2.5 2.5
Phosphate, mmoles/!iter 1.16 0.2 0.97 0.1 1.2 1.0
Bicarbonate, mmoles/!iter 12.9 1.3 12.0 1.4 13.5 13.3
25-(OH)D, nmoles/!Iter 34 19 45 26 60 110
24,25-(OH)2D, nmoles/!iter 10 4 11 5 10 7
1,25-(OH)2D, pmo!es/liier 437 180 323 62 654 288
iPTH, ng/ml 0.19 0.04 0.31 0.1 0.19 —
Other parameters
Creatinine clearance
ml/min/1.73 m2 130 33 76 9 122 78
Urinary calcium excretion,
mmo!es/kg body wi/day 0.07 0.02 0.07 0.05 0.16 0.12
Tubular reabsorption of
phosphorus, % 83 4 67 9 92 67
All data are given as the means si of mean values obtained for each subject. The individual mean values have been calculated with all data
from serial measurements performed between the 20th and the 30th to 36th month after renal transplantation. Subjects 9 to 13 (aged 9 to 17 years)
and 15 to 20 (aged 13 to 20 years) are presented in two groups according to their GFR. Subject 14 (aged Il years) is presented separately with mean
values of data obtained during the first 3 months (1st period) and during the following 10 months of investigation (2nd period).
b Plasma calcium concentrations have been corrected for plasma proteins [121.
Significant differences between subjects 9 to 13 and 15 to 20 are noted: P < 0.01.
between plasma 1 ,25-(OH),D and phosphate concentrations
when all assayed samples (during and after the initial peak)
were considered (r =
—0.04).
(2) Plasma metabolites in 12 patients between the 20th and
3Oth—36th month after kidney transplantation (long-term proto-
col). Data collected in the second protocol have been similarly
analyzed, and the subjects divided into two groups according to
their creatinine clearances.
During the period of investigation, five of the twelve children
and young adults had GFR's equal to or over 100 ml!min/l.73
m2 (three girls and two boys). Biochemical parameters re-
mained in the normal range during the entire length of the
followup, except plasma phosphate concentrations that de-
creased for short periods in two subjects. The lower plasma
phosphate concentration was 0.9 mmoles!Iiter. Plasma 24,25-
(OH)2D (5 to 21 nmoles/liter) and l,25-(OH)2D (180 to 800
pmoles/liter) were higher than normal values. In these patients,
a highly significant negative correlation was found between
1,25-(OH)2D and phosphate concentrations measured on the
same plasma samples (r = —0.91, P <0.001, Fig. 6). No
correlation was obtained between plasma 1 ,25-(OH)2D and any
of the other parameters, particularly iPTH or tubular reabsorp-
tion of phosphorus (only seven simultaneous measurements of
plasma 1 ,25-(OH)2D concentrations and of tubular reabsorption
of phosphorus could be analyzed). Plasma 24,25-(OH)2D con-
centrations could not be correlated to any of the measured
plasma or urinary parameters.
Six of the twelve patients had GFR's between 70 and 100 ml!
min/1.73 m2 during the investigation period (4 girls and 2 boys).
Their plasma creatinine concentrations were between 90 and
150 moles/liter, significantly higher than those found in the
former group of patients (Table 4). Their calcium concentra-
tions in plasma and urine, as well as their plasma bicarbonate
concentrations, remained in the normal range. Plasma phos-
phate concentration was low or at the lower limit of normal
values except in child 17. Tubular reabsorption of phosphorus
was low (between 55 and 78%). Plasma concentrations of iPTH
(0.15 to 0.56 ng!ml), 25-(OH)D (5 to 55 nmoles!liter), 24,25-
(OH)2D (4.5 to 17 nmoles/liter), and 1,25-(OH)2D (140 to 520
pmoles!liter) were not different from values found in patients
with normal GFR's. But, a major difference between the two
groups was observed when relating plasma l,25-(OH)2D and
phosphate concentrations measured on the same sample, be-
cause in the latter group no correlation was obtained (Fig. 6).
This difference in plasma 1 ,25-(OH)2D regulation could not
be explained by differences in age, sex, type of primary disease,
duration of hemodialysis before renal transplantation, presence
of radiological bone abnormalities, histocompatibility between
the allograft donors and the young recipients, warm and cold
ischemia times of the graft, therapeutic management of the
patients (phosphate, calcium, vitamin D intakes, administration
of antidiuretics fchlorothiazide], immunosuppressive treat-
ment, antyhypertensive drugs). None of these eleven patients
had proteinuria, glycosuria, or elevated aniinoaciduria.
Finally, in the last patient (child 14), the two observations of
very good and of moderately decreased GFR's were found
during the same investigation. In this patient, the GFR had been
over 100 mi/min/! .73 m2 and the plasma creatinine concentra-
tions had been lower than 100 mo1es!liter during the three first
months of the study. At this time, measured biochemical
parameters were similar to those found in patients 9 to 13 (Table
4). Plasma l,25-(OH)2D concentration was related to plasma
phosphate concentration (Fig. 6) During a second period,
creatinine clearance fell to between 70 and 80 ml/min!1.73 m2
and plasma creatinine increased to between 120 and 150
p.moles!liter. Although plasma calcium, bicarbonate, and phos-
phate concentrations did not vary significantly, a decrease in
tubular reabsorption of phosphate was observed. Plasma 1,25-
(OH)2D measured 5 and 8 months after the beginning of this
second period was no longer correlated with plasma phosphate
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concentrations. Similarly, in child 11, plasma concentrations of
I ,25-(OH)2D were not related any more to plasma phosphate
concentrations after the investigation period, when glomerular
function deteriorated (Fig. 6).
No catchup growth was observed during the followup in
children 9 to 13 (1 to 4 SD below normal height for chronologic
age), in children 15 to 20 (+1 to —5 SD), or in child 14 (—2 SD).
Discussion
The present investigation documents changes in plasma con-
centrations of renal 25-(OH)D hydroxymetabolites in young
patients having undergone kidney transplantation.
A first observation is the presence of both 24,25-(OH)2D and
1 ,25-(OH)2D in the 76 assayed plasma samples of these patients
at concentrations often markedly high. In 43 cases, the 24,25-
(OH)2D concentrations have been found higher than normal
limits [8], and the 1 ,25-(OH)2D plasma concentrations have
been either within normal limits in 16 samples or higher (60
samples).
Obvious methodologic errors may be dismissed for the fol-
lowing reasons. First, values found for 24,25-(OH)2D in plasma
of normal and kidney transplanted children have been measured
in the same laboratory with the same technique. Second, even
though the number of plasma samples assayed for I ,25-(OH)2D
in normal children is too limited to establish a normal range in
the present laboratory, values found in normal adults (mean
value, 89 pmoles/liter; range, 24 to 155 pmoles/liter) are similar
to normal values reported earlier. These values in adults,
slightly different from one laboratory to the other are (in
pmoles/liter) 79 (SD) 14 [14], 70 (SEM) 5 [15], 63 to 161 [16],
132 (SD) 24 [17], 82 (range, 48 to 125) [18], 99 (range, 53 to
142) [19], 89 (range, 30 to 160) [20J, and 86 (range, 43 to 163)
[21]. Third, results from l,25-(OH)2D assays, after a final
purification step on reverse-phase high-pressure liquid chroma-
tography, were similar to those obtained after straight-phase
high-pressure liquid chromatography. Finally, one of the puri-
fied fractions supposedly containing 1 ,25-(OH)2D has been
tested for biological activity in an in vitro system. Its presence
in the incubation medium stimulated the alkaline and the acid
phosphatase content of rat calvaria in a way similar to that of
synthetic l,25-(OH)2D3, and the calculated concentrations of
the presumed l,25-(OH)2D were comparable in the bioassay
and in the binding protein assay. Therefore, if there is, in the
plasma of transplanted children, a substance that interferes with
the I ,25-(OH)2D assay, this substance would have to (1) migrate
in the 1 ,25-(OH)2D3 peak fractions on three different chromato-
graphic systems (Sephadex LH2O, reverse-phase and straight-
phase high-liquid pressure chromatographies), and (2) exert in
vitro the biological activity of 1 ,25-(OH)2D. The presence of
such a substance, be it a vitamin D or a drug derivative, seems
unlikely although it cannot be totally excluded.
Wide fluctuations of both 24,25-(OH)2D and 1 ,25-(OH)2D
concentrations were observed in the plasma of the kidney-
transplanted children. In an attempt to gain insight into a
possible regulation of the dihydroxy metabolite plasma concen-
trations, we have examined simultaneously the changes in
circulating 25-(OH)D presursor, PTH, in phosphate and calci-
um metabolism, as well as the children's renal functions and
treatments. Circulating levels of 25-(OH)D remained in the
normal range in 16 of the 20 transplant subjects. Hence, it
cannot be argued that high values for dihydroxy metabolites
resulted from elevated body stores in 25-(OH)D. Elevated 1,25-
(OH)2D serum concentrations have been reported in hyperpar-
athyroid patients [14, 16], and PTH is considered a stimulating
factor of the renal l,25-(OH)2D synthesis [1]. Indeed, the four
patients with very high circulating 1 ,25-(OH)2D concentrations
in the first months after renal transplantation, had elevated
immunoreactive hormone plasma concentrations. But, PTH
does not seem to be the only stimulating factor of plasma 1,25-
(OH)2D in renal transplant children, because there was no
correlation between plasma I ,25-(OH)2D and iPTH concentra-
tions.
Phosphate concentrations in the circulating fluids or inside
the cell compartments may influence renal 1 ,25-(OH)2D synthe-
sis [1]. A significant inverse correlation has been demonstrated
in normal adults between plasma 1,25-(OH)2D and phosphate
concentrations [16]. In renal transplant children with normal
GFR's, such a correlation was found as from the first months
following transplantation (r = — 0.77, P < 0.001). This correla-
tion was even more significant in children studied during the
2nd and 3rd year after transplantation (r =
—0.91, P < 0.001).
Thus, phosphate appears to be a main regulating factor for
circulating 1 ,25-(OH)2D in children with kidney transplants who
have normal glomerular function. In these children, the correla-
tion was not identical to that described for normal adults [16],
and the question remains as to whether this difference is
secondary to a difference in age, to a difference between normal
and kidney transplant patients, or to both factors. Other factors
may modulate the phosphate influence, such as therapeutic
agent(s), elevated parathyroid secretion, and elevated sensitiv-
ity of the target cells to PTH.
It is interesting to note that plasma 1 ,25-(OH)2D in the young
patients with transplants resembles that in normal children even
when the kidney necrografts were obtained from adult donors.
Higher 1 ,25-(OH)2D concentrations in children may therefore
result more from environmental differences than from a higher
ability of the young kidney to hydroxylate 25-(OH)D into 1,25-
(OH)2D.
Renal function appears to be of critical importance in the
regulation of plasma l,25-(OH)2D concentrations. A slight
decrease in creatinine clearance (50 to 100 ml/min/l.73 m2) was
associated with the loss of correlation between plasma 1,25-
(OH)2D and phosphate concentrations. Further investigation
will be necessary to understand the mechanism for this lack of
l,25-(OH)2D response to plasma phosphate cencentrations,
even in the absence of multiple tubular dysfunction and of
constant hyperparathyroidism. Whether this is due to an inade-
quate renal 25-(OH)D-lc-hydroxylase activity or to a selective
damage of the phosphate transport in the kidney graft [5]
remains to be evaluated. The association of this abnormality
with a tubular phosphate leak and a moderate decrease in GFR
should be noted. In this group, plasma l,25-(OH)2D concentra-
tions similar to those found in patients with normal glomerular
function despite hypophosphatemia may be considered as re-
flecting a relative deficiency in l,25-(OH)2D. Although this
relative deficiency in 1 ,25-(OH)2D may not have been the major
factor responsible for the occurrence of hypophosphatemia in
the present patients, its role as a possible aggravating factor
cannot be dismissed. None of the child had a renal functon so
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altered that the reduced nephron mass would likely influence
1 ,25-(OH)2D synthesis.
In the four patients with subnormal creatinine clearances and
studied during the first year after transplantation, the above-
mentioned disturbance in plasma I ,25-(OH)2D regulation was
preceded by a rise in 1 ,25-(OH)2D plasma concentrations to
extremely high levels. This rise appeared only in children with
subnormal GFR's during the first months following renal graft
and coexisted with increased PTH circulating levels. Even
though the measured plasma compound had in vitro biological
activity, its presence at high concentrations in plasma was not
associated with evident signs of vitamin D intoxication such as
elevated calcium concentrations in plasma or urine.
Individual variations in 1 ,25-(OH)2D concentrations could
not be directly related to immunosuppressive therapy or to
other therapy (antihypertensive drugs, chlorothiazide, alumi-
num, cimetidine, phosphate supplements). In contrast, the
association of markedly elevated 1 ,25-(OH)2D concentrations
with furosemide administration seems to be worth further
clinical or experimental investigation. No period of catchup
growth following transplantation could account for the ob-
served changes in plasma 1 ,25-(OH)2D concentrations.
Finally, the evolution of 24,25-(OH)2D concentration in plas-
ma suggests the existence of a specific regulation. But it could
not be correlated with any of the factors known to stimulate
24,25-(OH)2D synthesis (calcium, PTH, I ,25-[OH]2D).
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